Speaker Name: Dr. Steve Bain, Clinical Director of the Diabetes Research Unit, Swansea University, Wales, UK.

Watch this insightful session to:

• Understand the primary SOUL result: reduction in 3-point MACE with oral semaglutide versus placebo in high-risk T2DM.
• Interpret effects on individual endpoints, including nonfatal MI, CV death, and nonfatal stroke.
• Review consistency of benefit across age, sex, BMI, kidney function, and baseline SGLT2 inhibitor use.
• Recognize secondary findings for renal outcomes, CV death, and major adverse limb events.
• Gain insight into the safety profile, including gastrointestinal discontinuation and no increase in serious adverse events.